Serious adverse events in study cohorts according to treatment in Apulia and Lombardy regions from 2010 to 2018
| Serious adverse events | Apulia | Lombardy | ||||||
| SGLT-2i (531) | GLP-1RA (459) | Insulin (7027) | Other AHAs (5704) | SGLT-2i (786) | GLP-1RA (759) | Insulin (10 950) | Other AHAs (8160) | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Hypoglycemia | 0 (0.0) | 0 (0.0) | 27 (0.4) | 18 (0.3) | 0 (0.0) | 2 (0.3) | 42 (0.4) | 42 (0.5) |
| Ketoacidosis | 0 (0.0) | 1 (0.2) | 7 (0.1) | 7 (0.1) | 1 (0.1) | 1 (0.1) | 7 (0.1) | 4 (0.1) |
| Diabetic coma | 0 (0.0) | 0 (0.0) | 9 (0.1) | 8 (0.1) | 0 (0.0) | 0 (0.0) | 22 (0.2) | 12 (0.2) |
| Syncope | 1 (0.2) | 4 (0.9) | 79 (1.1) | 95 (1.7) | 3 (0.4) | 6 (0.8) | 142 (1.3) | 117 (1.4) |
| Lower limb amputations | 6 (1.1) | 2 (0.4) | 109 (1.6) | 84 (1.5) | 7 (0.9) | 11 (1.5) | 323 (3.0) | 161 (2.0) |
| Fractures | 5 (0.9) | 9 (2.0) | 385 (5.5) | 392 (6.9) | 11 (1.4) | 28 (3.7) | 575 (5.3) | 535 (6.6) |
AHA, antihyperglycemic agent; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose cotransporter-2 inhibitor.